S&P Futures
4,048.50 -35.75 (-0.88%) Dow Futures
33,841.00 -205.00 (-0.60%) Nasdaq Futures
12,070.50 -151.75 (-1.24%) Russell 2000 Futures
1,902.40 -17.10 (-0.89%) Crude Oil
79.62 -0.06 (-0.08%) Gold
1,944.90 -0.70 (-0.04%)
Black Diamond Therapeutics, Inc. (BDTX)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 2.9900 |
| Open | 2.9900 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1200 |
| Day's Range | 2.9714 - 3.0500 |
| 52 Week Range | 1.1800 - 4.6200 |
| Volume | |
| Avg. Volume | 180,047 |
| Market Cap | 109.099M |
| Beta (5Y Monthly) | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.3350 |
| Earnings Date | Mar 15, 2023 - Mar 20, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.75 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BDTX
Related Research
- Black Diamond Therapeutics, IncDaily – Vickers Top Buyers & Sellers for 10/24/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat3 months agoArgus Research
- Simply Wall St.
private equity firms who own 40% along with institutions invested in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) saw increase in their holdings value last week
A look at the shareholders of Black Diamond Therapeutics, Inc. ( NASDAQ:BDTX ) can tell us which group is most...
- GlobeNewswire
Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the 41st
- GlobeNewswire
Black Diamond Therapeutics Announces Changes to Board of Directors
CAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that Chairman of the Board of Directors, Robert (Bob) A. Ingram, has stepped down due to personal reasons. Existing Board member, Mark Velleca, M.D., Ph.D., has been appointed to succeed Mr. Ingram as the next Chairman. “Bob’s counsel, expertise and partnership have
